Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region. The company develops Sofra, a platform designed to regulate innate immune signaling with greater precision; and Chroma, a small molecule technology platform focused on the development of multiple drug candidates for cancer treatment. It is also developing SOF-SKN, a topical therapy that has completed Phase I clinical trial for cutaneous lupus erythematosus; and CRO-67, a dual-cell preclinical drug candidate for the treatment of pancreatic cancer. In addition, the company intends to improve mRNA vaccines. Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.
Price analytics
Returns
1 day
0.0%
1 week
-1.7%
1 month
-26.2%
3 months
-37.9%
6 months
1.7%
1 year
-35.2%
3 years
-46.4%
Risk
Volatility (1y ann.)
99.0%
Beta vs ASX 200
0.71
Sharpe (1y)
-0.01
VaR 95% (1-day)
-9.1%
Max drawdown (1y)
-45.7%
Off 1-year high
-43.8%
Technicals
RSI(14)
21
OS
vs 50DMA
-23.2%
vs 200DMA
-22.2%
Trend
Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value72.7
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
100
Price / Sales
0
Growth—
Revenue growth (1y)
—
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health0.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
0
Debt / Equity
—
Quality (Profitability & Cash Flow)34.8
Return on equity
—
Return on assets
0
Operating margin
100
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum15.7
6-month return vs ASX 200
40
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
14
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).